In addition, it has been demonstrated that AXL activation is involved in the generation and maintenance of DTCs in lung cancer treated with axitinib, and that the application of AXL inhibitors in combination with targeted drugs is effective in preventing DTCs both in vitro and in vitro (39). The gene discussed is AXL; the disease is lung carcinoma.